Congress vs. Pharma Trouble Ahead?
Now that the 2006 midterm elections are over, the pharmaceutical industry is left to ponder what the new Congress has in store for it. This article is a summary of a Pharma Marketing Roundtable discussion of the Congressional agenda for pharma (real and feared). The article includes results from the online “What’s In Store From Congress” survey.
Listen to the following podcast discussion:
Topics covered include:
- Medicare Part D Reform
- Mandatory Pre-Clearance of DTC
- Black Triangle Label for New Drugs
- Worst Case/Best Case Scenarios
Read this article now. It’s FREE…
Issue: Vol. 5, No. 10: December 2006
Word Count: 3206